Sirigen Raises $6.1M for Technology Commercialization | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK amplification firm Sirigen today announced it has raised about £3.8 million ($6.1 million) in two completed rounds of financing, which it will use to support commercialization of its High Sensitivity Fluorescence technology.

Leading the rounds was a syndicate of new investors including IQ Capital, the National Endowment for Science, Technology, and the Arts, and YFM Private Equity. Existing investors Seraphim Capital and Oxford Capital Partners also participated.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.